The CHM Biobank at North-West University was Africa’s first biobank dedicated to rare diseases. Established in 2019 as part of the National Metabolomics Platform (NMP), it builds on work started in 1983 at the Potchefstroom Laboratory for Inborn Errors of Metabolism (PLIEM). It began with just three samples and today holds samples from more than 834 participants, making it a key contributor to rare disease research on the continent.
Its focus has always been on rare diseases, especially inborn errors of metabolism. The biobank collects blood, urine, and DNA samples, primarily from individuals affected by rare genetic disorders, with the majority of samples linked to inborn errors of metabolism. These samples support a wide range of research, including genetic testing, the development and optimisation of diagnostic methods, understanding disease patterns, and participation in genome studies such as Whole Exome and Whole Genome Sequencing.
What makes the CHM Biobank unique is that it’s the first of its kind in Africa focused on rare diseases. It holds broad consent for research and is working toward ISO 20387 accreditation. It also aims to become a training hub for biobank operations in Africa, sharing its expertise with others on the continent.
The biobank plays an important role in making advanced diagnostics more accessible. In collaboration with DIPLOMICS and the NMP, it supports a national study to bring genetic testing capabilities into South Africa. This reduces the need to send samples overseas and speeds up diagnosis for patients.
The CHM Biobank also stores the South African samples for the International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) study. It receives research requests from local and international researchers, including partners like the Mayo Clinic.
As part of the MBirSA network, the biobank benefits from shared expertise, improved infrastructure, and national visibility. This helps it to expand sample collection across all provinces, strengthen ethical and data standards, and increase its impact through new collaborations.
Future plans include more research on rare diseases, increased public awareness, and further support for international partnerships. With help from MBirSA, the CHM Biobank is growing its contribution to both local and global research — and helping to make sure African patients are part of the future of precision medicine.
